Drugs / Muscadine grape extract
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial · 1 missed | ||||||
| Phase 0 | NCT04495751 | Apr 2021 → Aug 2024 | — | Wake Forest University Health Sciences | Completed | Missed primary |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03496805 | Jan 2019 → Feb 2025 | prostate carcinoma | Wake Forest University Health Sciences | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | muscadine grape extract | “Our preclinical and clinical data show promising effects of a muscadine grape extract supplement (MGES) on oxidative stress, mitochondrial bioenergetics, the microbiome, and...” PMID 36990930 ↗ Mar 20231“muscadine grape extract (MGE)” NCT03496805 ↗ |
| Known as | MGE | “muscadine grape extract (MGE)” NCT03496805 ↗ |
| Known as | MGES | “Our preclinical and clinical data show promising effects of a muscadine grape extract supplement (MGES) on oxidative stress, mitochondrial bioenergetics, the microbiome, and...” PMID 36990930 ↗ Mar 2023 |
| Route | Oral | “receive muscadine grape extract orally (PO)” NCT03496805 ↗ |